CARL MCLEMORE: Open Payments
NPI 1073513941 · NEW ROADS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,538 in 95 payments from 25 companies in 2025. Trend: 2023 $1,288 · 2024 $1,360 · 2025 $1,538
Food & beverage: $1,538
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 17 | $257 |
| ABBVIE INC. | 20 | $217 |
| Novo Nordisk Inc | 11 | $173 |
| PFIZER INC. | 6 | $121 |
| Abbott Laboratories | 5 | $97 |
| GlaxoSmithKline, LLC. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 2 | $57 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
Products named: JARDIANCE, VRAYLAR, FREESTYLE LIBRE 3, Rybelsus, REXULTI, ELIQUIS, CAPLYTA, Ozempic.
Industry payments across LA — which companies pay providers there.
